Pfizer reveals full costs of $23bn jumbo
Pfizer, the US drugs group which last week announced a $68bn acquisition of local rival Wyeth, has released more details about its $22.5bn acquisition loan. The filing with the US Securities and Exchange Commission late last week reveals just how expensive bank debt has become for borrowers seeking jumbo facilities.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ European securitization issuance database
- ✔ Daily newsletters across markets and asset classes
- ✔ 1 weekly securitization podcast
